Gefitinib and erlotinib targeting epidermal growth factor receptors have been used in the treatment of lung cancer, and EGFR polymorphism has been found to be associated with toxicity associated with tyrosine kinase inhibitors [7]. Here, EGFR is linked to lung carcinoma.